BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 18446708)

  • 1. The middle-molecule hypothesis 30 years after: lost and rediscovered in the universe of uremic toxicity?
    Vanholder R; Van Laecke S; Glorieux G
    J Nephrol; 2008; 21(2):146-60. PubMed ID: 18446708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bench to bedside view of uremic toxins.
    Vanholder R; Baurmeister U; Brunet P; Cohen G; Glorieux G; Jankowski J;
    J Am Soc Nephrol; 2008 May; 19(5):863-70. PubMed ID: 18287557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracorporeal strategies for the removal of middle molecules.
    Winchester JF; Audia PF
    Semin Dial; 2006; 19(2):110-4. PubMed ID: 16551287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and clinical evidence for uremic toxicity.
    Bouré T; Vanholder R
    Artif Organs; 2004 Mar; 28(3):248-53. PubMed ID: 15046622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical and metabolic consequences of uremic toxicity].
    Rutkowski P
    Przegl Lek; 2006; 63(4):209-17. PubMed ID: 17080744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uremic toxins: do we know enough to explain uremia?
    Vanholder R; Meert N; Schepers E; Glorieux G
    Blood Purif; 2008; 26(1):77-81. PubMed ID: 18182802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should dialysis modalities be designed to remove specific uremic toxins?
    Baurmeister U; Vienken J; Ward RA
    Semin Dial; 2009; 22(4):454-7. PubMed ID: 19709001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of uremic toxicity.
    Vanholder RC; Glorieux GL
    Hemodial Int; 2003 Apr; 7(2):156-61. PubMed ID: 19379356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Uremic toxins: the case of protein-bound compounds].
    Basile C; Libutti P; Teutonico A; Lomonte C
    G Ital Nefrol; 2010; 27(5):498-507. PubMed ID: 20922681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uremic toxins: a new focus on an old subject.
    Yavuz A; Tetta C; Ersoy FF; D'intini V; Ratanarat R; De Cal M; Bonello M; Bordoni V; Salvatori G; Andrikos E; Yakupoglu G; Levin NW; Ronco C
    Semin Dial; 2005; 18(3):203-11. PubMed ID: 15934967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Uremic middle-molecule toxins and their removal in hemofiltration].
    Kazakov IV; Timokhov VS
    Urol Nefrol (Mosk); 1991; (1):67-73. PubMed ID: 1858215
    [No Abstract]   [Full Text] [Related]  

  • 13. [Uremic toxins].
    Vanholder R
    Nephrologie; 2003; 24(7):373-6. PubMed ID: 14650749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathophysiological aspects of neurological complications in renal failure.
    De Deyn PP; Saxena VK; Abts H; Borggreve F; D'Hooge R; Marescau B; Crols R
    Acta Neurol Belg; 1992; 92(4):191-206. PubMed ID: 1332359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet/Leukocyte activation, inflammation, and uremia.
    Glorieux G; Cohen G; Jankowski J; Vanholder R
    Semin Dial; 2009; 22(4):423-7. PubMed ID: 19708994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro cytotoxic properties of plasma fractions from uremic patients.
    Delaporte C; Gros F; Jonsson C; Bergström J
    Artif Organs; 1981; 4 Suppl():68-70. PubMed ID: 7295099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The gut: the forgotten organ in uremia?
    Schepers E; Glorieux G; Vanholder R
    Blood Purif; 2010; 29(2):130-6. PubMed ID: 20093818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Middle-molecular uremic toxins (review of the literature)].
    Tupikova ZA
    Vopr Med Khim; 1983; 29(1):2-10. PubMed ID: 6340339
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential role of middle molecular compounds in the development of uremic anemia.
    Leber HW; Debus E; Grulich U; Schütterle G
    Artif Organs; 1981; 4 Suppl():63-7. PubMed ID: 7295098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of clinical implications of middle molecules and their kinetics in uremia.
    Funck-Brentano JL; Man NK
    Artif Organs; 1981; 4 Suppl():125-32. PubMed ID: 7295078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.